A method is presented for the quantitative measurement of lysergide (LSD) and its metabolite 2-oxo-3-hydroxy-LSD (O-H-LSD) in urine and blood. O-H-LSD has been reported to have urinary concentrations many times higher than LSD. Measuring its presence in urine would significantly extend the detection lime for confirming LSD abuse. A single-step liquid-liquid extraction was performed on 5-mL urine samples prior to separation by gradient liquid chromatography (LC). Electrospray ionization was used to produce the positively charged ions of O-H-LSD, 2-oxo-3-hydroxy-LAMPA (O-H-LAMPA, internal standard), LSD, and iso-LSD. Varying the orifice voltage in the intermediatepressure region of the source generated the fragmentation necessary to produce qualifying ions. Selected ion moniloring allowed detection limits of 400 pg/mL and 100 pg/mL for O-H-/SD and LSD, respectively. The method was linear for O-H-LSD from 400 to 8000 pg/mL and for LSD from 100 to 6000 pg/mL. LSD-positive samples (n = 9) analyzed by the liquid chromatography-mass spectrometry method were found to contain mean concentrations of 6378 pg/mL O-H-LSD (332-21371 pg/mL) and 844 pg/mL LSD (177-2456 pg/mL). O-H-LSD urinary concentrations were between 0.9 and 19.8 times higher than LSD (mean --10.2).
Lysergic acid diethylamide (LSD, lysergide) is one of the most potent hallucinogenic chemicals known to man. LSD produces unique challenges to the forensic toxicologist. Measurement of LSD in biofluids has traditionally required attention to the parent compound. Controlled studies of LSD pharmacokinetics have largely been restricted to animal models (1,2) because of the ethical and legal restrictions of administering hallucinogens to humans. However, limited studies have demonstrated the metabolism of LSD to N-demethyl-LSD, 2-oxo-LSD, and 13-and 14-hydroxy-LSD glucuronide in humans (3, 4) . Successful identification of LSD in urine has been dependent upon collecting a sample prior to quantitative metabolism and detection methods with picograms-per-milliliter sensitivity.
Several reviews dealing with chromatographic and mass spectrometric methods for confirming LSD in biological samples have been published (4) (5) (6) . Gas chromatography-mass spectrometry (GC-MS) has proven a very sensitive method for LSD detection. Publications using selected ion monitoring (SIM) (7) , chemical ionization selected reaction monitoring (SRM) (8) , and ion-trap tandem MS (9) have demonstrated detection limits on the order of 10 to 30 pg/mL.
Recently, a major LSD metabolite was identified as 2-oxo-3-hydroxy-LSD (O-H-LSD) (6, 10) . O-H-LSD and LSD have been measured in urine by GC-MS using SIM (11) and positive ion chemical ionization SRM (12) modes. The metabolite urinary concentrations have been measured up to 136 times higher than LSD (11) . Formation of the trimethylsilyl (TMS) derivatives of O-H-LSD and LSD was required for analysis by GC-MS procedures.
The application of liquid chromatography-mass spectrometry (LC-MS) for clinical and forensic toxicology has recently been reviewed (13) . LC allows the analysis of polar and thermolabile analytes that are otherwise difficult to separate by GC. Poch et al. (14) used LC-MS-MS to analyze the ratios of O-H-LSD to LSD in 74 urine samples. A mean O-H-LSD/LSD ratio of 42.9 was found with a range of 1.1 to 778.1. O-H-LSD was detected in all of the samples with 34 of the samples (46%) containing LSD concentrations below the Department of Defense (DOD) cutoff value of 200 pg/mL. These results supported the authors' conclusion that measurement of O-H-LSD could extend the window of detection beyond that provided by the parent compound.
An LC-MS method using electrospray ionization has been developed by our laboratory for the quantitative detection of O-H-LSD and LSD in biological samples. The method employed a single step liquid-liquid extraction for urine samples and a combined liquid-liquid and solid-phase extraction for whole blood samples without the need for extract derivatization. Mass detection using a single quadrupole benchtop instrument was preferred over the complexity and cost of tandem MS instruments.
Electrospray ionization generally results in the production of spectra consisting solely of the molecular ion. The application of alternating orifice voltages in the intermediate pressure region of the source allowed the production of additional, qualifying fragment ions. Urine samples from LSD abusers were analyzed for O-H-LSD and LSD using this procedure and the conjugation of O-H-LSD with glucuronic acid was explored by enzymatic hydrolysis of urine samples. The method was amenable to whole blood samples when additional sample cleanup was conducted.
Experimental

Chemicals and reagents
All reagents were analytical or HPLC grade. LSD was purchased from Alltech-Applied Science (Deerfield, IL). 2-Oxo-3-hydroxy-LSD, 2-oxo-3-hydroxy-LAMPA (O-H-LAMPA, IS), iso-LSD, and morphine-d3 were purchased from Radian Int. (Austin, TX). Solid-phase extraction columns were purchased from United Chemical Technologies (Bristol, PA). Certified drugfree urine containin~ 0.1% sodium azide was purchased from Bio Rad Laboratories (lrvine, CA). [3-Glucuronidase (EC 3.2.1.31, Helix pomatia) with glucuronidase activity of 132,500 Fishman units (FU)/mL and sulfatase activity up to 5000 sulfatase units (SU)/mL was purchased from Sigma (St. Louis, MO). Morphine 3-[3-D-glucuronide (M3G) was also purchased from Sigma.
Stock solutions
Stock solutions of LSD and iso-LSD were prepared in acetonitrile at concentrations of 0.001 mg/mL and 0.1 IJg/mL, respectively. The solutions were stored in amber vials at -]5~ A stock solution of O-H-LSD was prepared in acetonitrile at a concentration of 0.001 mg/mL. A working solution of O-H-LAMPA was prepared in acetonitrile at a concentration of 0.001 mg/mL. Both the O-H-LSD and O-H-LAMPA solutions were stored in amber vials at -15~
The stock solutions were used to prepare calibration and control standards in negative urine. Calibration and control samples were stored in polypropylene containers at 4~
Samples
Urine and whole-blood samples were collected from activeduty United States military personnel during the normal course of the DOD military drug-testing program or as a result of command-directed action. The urine samples had previously
544
Journal of Analytical Toxicology, Vol. 24, October 2000 screened positive for LSD by either microplate enzyme immunoassay (STC Tech., Bethlehem, PA) or radioimmunoassay (DPC, Los Angeles, CA) at a cutoff concentration of 500 pg/mL and had been confirmed by GC-MS-MS (8) using a 200-pg/mL concentration cutoff. Blood samples were stored in gray-top vacutainer tubes. Blood and urine samples were stored frozen at -20~
Extraction
To 5 mL of urine samples, calibrators, and controls were added 0.25 g sodium chloride and 20 IJL of O-H-LAMPA internal standard (4000 pg/mL). The urine was alkalinized by the addition of 0.1 mL concentrated ammonium hydroxide followed by the addition of 5 mL methylene chloride containing 15% isopropanol (by volume). After vortex mixing the sample for 30 s, the tubes were mixed on a platform shaker for 30 min at approximately 60 cycles/rain.
The two layers were separated by centrifugation at 2500 rpm for 15 rain. The organic layer was removed to labeled 10-mL conical centrifuge tubes and evaporated under nitrogen at 45~ in a Turbovap LV evaporator (Zymark Corp., Hopkinton, MA). The extracts were reconstituted in 200 1JL of LC mobile phase comprised of 70% 20raM ammonium formate (pH 4.3) and 30% methanol. After brief vortex mixing, the tubes were centrifuged for 5 min and the extracts transferred to polypropylene autosampier vials. An injection volume of 90 IJL was routinely required to achieve the necessary sensitivity.
For the analysis of O-H-LSD and LSD in blood samples, 1 mL of whole blood was added to a 16 x 100-ram glass tube containing 0.25 g NaCl. Four milliliters of deionized water and 20 IJL internal standard were added. The liquid-liquid extraction used for urine samples was performed on the blood. However, following evaporation, the blood samples were reconstituted in 2 mL 0.1M phosphate buffer (pH 6). Solid-phase extraction columns (CSDAU203, United Chemical Technologies, Bristol, PA) were conditioned with 3 mL methanol, 3 mL deionized water, and 1 mLpH 6 phosphate buffer. After the samples were passed through the columns, they were washed with 3 mL water, 1 mL 1M acetic acid, and 3 mL of methanol containing 40% water. The drugs were eluted with 3 mL of 2% ammonium hydroxide in methylene chloride/isopropanol (80:20).
Enzymatic hydrolysis was used to evaluate the presence of O-H-LSD glucuronide and, to a lesser degree, sulfate metabolite conjugates. The [3-glucuronidase activity was first confirmed by incubating 1-mL urine samples containing M3G and morphined3 (4000 ng/mL). The sample pH was adjusted to pH 5 by the addition of ] mL 0.1M acetate buffer (pH 5), after which 101JL of the enzyme was added (1325 FU/mL). The tubes were incubated at 37~ for 24 h and analyzed by GC-MS using the method of Paul et al. (15) .
After confirming the glucuronidase activity, duplicate urine samples (5 mL) were prepared from previously confirmed LSDpositive specimens. One set was extracted as described, and the second was hydrolyzed as follows. Two milliliters of 0.1M acetate buffer (pH 5) and 150 tJL of [3-glucuronidase (3975 FU/mL urine, maximum of 150 SU/mL) was added to each sample. The tubes were capped and incubated in a water bath at 37~ for 24 h. The tubes were incubated in the dark because of the light sensitivity of the enzyme. After hydrolysis was complete the samples were extracted as previously described.
LC-MS analysis
Quantitation was carried out using an Agilent Technologies (Palo Alto, CA) 1100 series mass selective detector (MSD) operating in electrospray ionization (ESI), selected ion monitoring, positive ion mode. Instrumental operation and data analysis were performed using the Agilent LC-MSD Chemstation Revision A.06.03 (509) software. Separation of O-H-LSD, O-H-LAMP& and LSD was done using an Agilent Technologies 1100 LC made up of a vacuum degasser, binary pump, temperaturecontrollable column compartment, and autosampler containing a 250-pL sample loop.
The separation column was an Eclipse XDB-C18 75-mm x 4.6-mm i.d. with a 3.5-pro particle size (Agilent Tech.). The column was equipped with a 12-mm x 4.6-ram guard column (Eclipse XDB-C18, 5-1am particle size). The flow rate was set to 0.7 mL/min, and the column compartment was maintained at 30~ Gradient elution began with a mobile phase of 70% 20raM ammonium formate at pH 4.3 (A) and 30% methanol (B). The 70 (A):30 (B) composition was held for 5 rain, and then the per- Analyzed over five days (n = 5).
n=3, 
raised the total analysis time to 15 rain.
The ESI interface used nitrogen for both pneumatic-assisted nebulization and as the drying gas. The nebulizer pressure was set to 40 psi, and the drying gas flow and temperature were set to 13 L/min and 350 ~ C, respectively.
Ion transmission to the MSD was accomplished using a capillary voltage of 2kV and was optimized for each ion by dynamic ramping of the orifice voltage. Optimal orifice voltages were determined by flow injection analysis of unextracted standards (1000 pg/pL).
The MSD tune was monitored daily by executing the automated checktune function of the LC-MSD Chemstation software. Full tuning of the instrument was not routinely done, as it would alter the optimized orifice voltages. A peakwidth of 0.08 min, a cycle time of 0.48 s/cycle, and a dwell time of 152 ms were assigned for each ion monitored. Setting a gain equal to 6 provided sufficient sensitivity for analysis.
The 
Method validation
Linearity was assessed by the analysis of O-H-LSD and LSD standards in urine on three separate days. Six O-H-LSD calibrators ranging from 400 to 8000 pg/mL and seven LSD calibration standards in the range of 100-6000 pg/mL were extracted in duplicate on each day.
Within-day precision was determined by analyzing five urine aliquots for each of three concentrations of O-H-LSD (500, 2000, and 8000 pg/mL) and LSD (150, 400, and 1600 pg/mL). Intermediate precision was determined by quantitative measurement of O-H-LSD (400, 1000, 4000, and 8000 pg/mL) and LSD (100, 200, 800, 1600, and 4000 pg/mL) over a five-day period. Extraction recovery was determined in urine and whole blood at three concentrations for O-H-LSD (2000, 4000, and 8000 pg/mL) and LSD (200, 800, and 1600 pg/mL). For each concentration,
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internal standard was added to six urine and six whole blood samples either with O-H-LSD and LSD (n = 3) or without (n = 3). Following extraction, the negative samples were spiked to the appropriate concentration with O-H-LSD and LSD prior to evaporation and analysis. 
Results
The procedure was linear for O-H-LSD over the concentration range of 400-8000 pg/mL. The correlation coefficient for the three-day linearity study was 0.9939 with individual day linearity as high as R 2 = 0.9984. The three day linearity for LSD gave a correlation coefficient of 0.9923 and an individual day linearity maximum of R 2 = 0.9997. The dynamic range of LSD, using O-H-LAMPA as internal standard, ranged from 100 to 6000 pg/mL. Table I lists the precision and accuracy for the LC-MS measurement of O-H-LSD and LSD.
Within-day coefficients of variation (%CV) were less than 4.0% for O-H-LSD and less than 6.0% for LSD, whereas intermediate day %CVs were less than 15% and less than 9.0% for O-H-LSD and LSD, respectively. All precision samples quantitated within • 15% of their target values.
O)
.c: The extraction recovery of O-H-LSD in urine was in the range of 69-74%. LSD gave similar recoveries in urine of 66--68%. The percent recovery of O-H-LSD in whole blood was 32--42% with recoveries of LSD between 31 and 61%.
The limit of detection (LOD) and limit of quantitation (LOQ) were determined by measuring urine extracts that contained decreasing concentrations of O-H-LSD and LSD. The LOD/LOQ was determined to be 400 pg/mL for O-H-LSD and 100 pg/mL for LSD in urine. Table II lists 
Discussion
Because of the relatively soft ionization process of electrospray ionization, mass spectra typically consist of a single prominent molecular ion. By increasing the orifice voltage applied to the analyzer end of the sampling capillary, fragmentation of the molecular ion can be produced through collisions with drying gas and residual mobile phase solvent. Figures 1 and 2 show the effect of increasing orifice voltage on the fragmentation of O-H-LSD and LSD. As the orifice voltage is raised from 90 V to 140 V an increase in fragment ion abundance is accompanied by decreasing molecular ion abundance. The orifice voltages resulting in the optimal signal for each SIM ion were selected, and the voltage was alternated for each mass specified in the acquisition scan. Alternating the orifice voltage produced consistent qualifier ion abundances for confirmation of O-H-LSD and LSD identities.
Preliminary work on this method involved the use of two internal standards, O-H-LAMPA and LAMPA. Maintaining isocratic conditions for separation resulted in 20-min run times and co-elution of iso-LSD with LAMPA ( Figure 3A) . A gradient program was selected to lower the retention times. The gradient shortened the time; however, iso-LSD and LAMPA were poorly resolved ( Figure 3B) . Removal of the LAMPA internal standard provided good resolution of analytes within 11 min ( Figure 3C ). The quantitation of LSD using the O-H-LAMPA internal standard was accurate (Table I) , and LSD was well resolved from iso-LSD.
In 8 of the 9 urine samples analyzed, the concentration of O-H-LSD was higher than that of LSD (Table II) . In two of the samples with LSD concentrations below the DOD cutoff, O-H-LSD was present at more than 17 times the amount of LSD. The average values of O-H-LSD were 10.2 times higher than LSD, confirming earlier observations that determination of LSD abuse based upon O-H-LSD measurement could extend the time course for detection (14) . Iso-LSD was present in eight of the urine samples (samples 1-7 and 9) and the four blood samples containing LSD. The presence of iso-LSD in body fluids is the result of contamination in the illicit preparation of LSD (6) . The relative concentrations of iso-LSD to LSD have been shown to vary widely in urine (14) .
A
comparison of the original LSD concentrations determined by GC-MS-MS with the LC-MS
A values showed good agreement (Table II) . The values for samples 2, 3, and 4 were 32, 24, and 25% lower, respectively, than the original GC-MS--MS values, possibly reflecting the effect of long-term storage on the stability of LSD.
Representative ion chromatograms for the ' limit of detection in urine (400 pg/mL), a negative B urine sample, and an O-H-LSD-positive sample (sample 5; 21371 pg/mL) are shown in Figure 4 . Figure 5 shows the ion chromatograms for the limit of detection of LSD (100 pg/mL), and both LSD and iso-LSD found in the urine and blood of . . . . ff-Glucuronidase from H. pomatia was used exclusively and specifically for two reasons. ,, Enzyme preparations from mollusks contain sul-B fatase activity, whereas E. coli and bovine liver preparations do not. As the number and volume of samples were limited in this work, additional and broader hydrolytic activity was preferred. Furthermore, the limitations imposed by the amount of sample did not provide for replication ,', of hydrolysis experiments using alternative hydrolysis set, it is not possible to draw a conclusion as to the relevance of this increase except to say that the experiment deserves further attention with a larger sample set including higher O-H-LSD concentrations.
Whole-blood samples accompanied six of the urine samples tested. A solid-phase cleanup step was required in addition to the liquid-liquid extraction before the blood samples could be analyzed. This was due to the difficulty in separating cellular components of the hemolyzed blood from the initial extract. As the injection volume for the LC separation was 90 pL, particulate matter present in the initial extract would result in column plugging and increased pump pressures. A combination of the additional sample extraction and the complexity of the blood matrix resulted in decreased analyte recoveries and higher detection limits compared to urine samples.
The LC-MS method achieved low level detection limits for both analytes with added confidence of identification by the formation of qualifying ions. Sample extraction was minimal because of the added discrimination of background effects available with electrospray ionization. The usefulness of 2-oxo-3-hydroxy-LSD as evidence of LSD abuse is shown by the higher urinary concentrations it has relative to the parent drug. Monitoring O-H-LSD will afford more confidence in the detection of LSD use because the time allowed for detection will be increased while the complexity and sensitivity of the instrumentation required for confirmation is reduced.
